Explorez tous les épisodes du podcast A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy
| Titre | Date | Durée | |
|---|---|---|---|
| Principles of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma: Patient Selection Strategies | 09 juin 2022 | 00:08:02 | |
Large B-cell lymphomas (LBCLs) are one of the most common subtypes of non-Hodgkin lymphomas and while 1st-line standard of care has remained unchanged, the treatment paradigm has undergone a shift in recent years due to the development of novel therapeutic agents. These novel therapies include monoclonal antibody (mAb) therapies, mAb-conjugates, and chimeric antigen receptor (CAR)-T cell therapies. | |||
| Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies | 09 juin 2022 | 00:36:58 | |
Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies | |||
| Disease Burden and Overview of Large B-Cell Lymphomas | 09 juin 2022 | 00:04:04 | |
B-cell lymphomas consist of a heterogenous group of lymphoproliferative neoplasms originating from B-lymphocytes. | |||
| Management of Adverse Effects Associated With Novel Therapies | 09 juin 2022 | 00:13:25 | |
Management of relapsed/refractory LBCLs remains a substantial and persistent clinical challenge, including optimal treatment sequencing, therapy evaluation and patient selection, and toxicity management. | |||